ArticleResearch and practice in thrombosis and haemostasis2021
A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study.
Article in Research and practice in thrombosis and haemostasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Scoping review of patient and family engagement interventions in diagnosis: a paradox of too much, yet so little.BMJ quality & safety · 2026Article
- Awareness of Venous Thromboembolism in Patients With Cancer and Their Carers: Protocol for Systematic Review.Thoracic cancer · 2025Article
- Patient's Awareness of Cancer-Associated Thrombosis: A Canadian Nationwide Survey.TH open : companion journal to thrombosis and haemostasis · 2025Article
- Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.BMC cancer · 2024Article
- Cancer-Associated Thrombosis: Trends in Clinical Features, Treatment, and Outcomes From 2001 to 2020.JACC. CardioOncology · 2023Article
- A systematic approach to venous thromboembolism prevention: a focus on UK experience.Research and practice in thrombosis and haemostasis · 2023Article
- Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day.Journal of thrombosis and haemostasis : JTH · 2022Article
- Cancer patients' experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).PloS one · 2022Observational
- Article
- Série « Prévenir la thrombose »: Sensibiliser les professionnels de la santé à la thrombose liée au cancer.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2022Article
- A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study.Research and practice in thrombosis and haemostasis · 2021Article
- Article
- The significance of VTE in cancer: Introduction of the 'Spot the CLOT' series.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
introductionVenous thromboembolism (VTE) is a common and serious complication of systemic anticancer therapies. Delays in presentation increase risk of death or long-term morbidity.
backgroundA patient charity developed an information video for patients receiving systemic anticancer therapy including what to do if they developed symptoms of VTE. This was introduced into clinical practice in a regional cancer center and its impact compared with a district general hospital where the video was not used.
methodsA mixed-methods approach was used, comprising clinical audit data, patient surveys, and key informant interviews. The time between development of VTE symptoms and seeking medical evaluation was routinely recorded on patients attending a regional cancer-associated thrombosis service with systemic anticancer therapy-provoked VTE. The video was then embedded into clinical practice at the regional cancer center for 3 months. The primary outcome was the difference in time to presentation with VTE symptoms, between patients attending the regional cancer center and the district general hospital (which acted as control). Other outcomes included impact on radiology resources, patient knowledge, and perspectives of chemotherapy nurses.
resultsAddition of the video was associated with a lower mean time to presentation from 8.9 to 2.9 days (0.33 hazard ratio; 95% confidence interval, 4.5-7.4;
conclusionThe video was associated with reduced delays in diagnosis of systemic anticancer therapy-associated VTE by 6 days, thereby reducing long-term complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.